Xanamem depression trial published in British J Psychiatry

• Xanamem shows meaningful anti-depressant activity in difficult-to-treat population
• No correlation between cognitive improvement and depression improvement
• Xanamem safe and well-tolerated

Actinogen Medical Limited has announced the publication of results from its phase 2 trial of Xanamem (emestedastat) in the British Journal of Psychiatry. The trial, designed to assess the drug's potential as a novel antidepressant, enrolled 165 participants with major depressive disorder and cognitive impairment. Key findings include meaningful anti-depressant activity, particularly in patients on SSRI medication, and the absence of a correlation between cognitive and depressive symptom improvements. Xanamem demonstrated safety and tolerability, with no significant adverse effects reported.